Dynamics of circulating VEGF-A predict benefit from anti-angiogenic cediranib in metastatic or recurrent cervical cancer patients
Tugwood, Jonathan D
Simpson, Kathryn L
Jayson, Gordon C
Davidson, Susan E
West, Catharine ML
AffiliationDivision of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
MetadataShow full item record
AbstractBACKGROUND AND PURPOSE: There is a need for predictive and surrogate response biomarkers to support treatment with anti-angiogenic VEGF inhibitors. We aimed to identify a minimally-invasive biomarker predicting benefit from cediranib pre-treatment or early during treatment in patients with recurrent or metastatic cervical cancer. EXPERIMENTAL APPROACH: Blood samples were collected before treatment, during treatment and upon disease progression where appropriate from patients enrolled in CIRCCa, a randomised phase II trial of carboplatin and paclitaxel with or without cediranib. Plasma concentrations of VEGF-A, VEGF-R2, Ang1 and Tie2 were measured using multiplex ELISA. Pre-treatment and temporal changes of the biomarkers were investigated using proportional hazard regression and unsupervised clustering analysis. KEY RESULTS: Samples (n=556) from 52 patients were analysed. VEGF-R2 (p=0.0006) and Tie2 (p=0.04) were down-regulated following cediranib, while VEGF-A (p=0.0025) was up-regulated. High ECOG performance status (p=0.02, HR=2.15, 95%CI 1.13-4.09) and low pre-treatment Tie2 concentrations (p=0.003, HR= 0.57, 95%CI 0.39-0.83) were independent prognostic factors associated with reduced progression-free survival. Two patterns of changes in VEGF-A following cediranib were identified. Patients with elevated VEGA-A in the first 3 treatment cycles, regardless of magnitude, had reduced progression-free survival in the placebo arm but improved survival with the addition of cediranib (p=0.019, HR= 0.13, 95% CI 0.02-0.71). CONCLUSIONS AND IMPLICATIONS: Patterns of early elevation in plasma VEGF-A should be studied further as a potential biomarker to predict treatment benefit from cediranib.
CitationZhou C, Taylor S, Tugwood J, Simpson K, Jayson GC, Symonds P, et al. Dynamics of circulating VEGF-A predict benefit from anti-angiogenic cediranib in metastatic or recurrent cervical cancer patients. Br J Clin Pharmacol. 2019.
JournalBritish Journal of Clinical Pharmacology
- Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
- Authors: Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M, Hudson E, Reed N, Flubacher M, Jankowska P, Powell M, Dive C, West CML, Paul J
- Issue date: 2015 Nov
- Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
- Authors: Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM
- Issue date: 2013 Apr 2
- Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
- Authors: Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK
- Issue date: 2010 Jun 10
- Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
- Authors: Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA
- Issue date: 2015 Nov
- Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
- Authors: Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB, ICON6 collaborators.
- Issue date: 2016 Mar 12